BeOne Medicines (NASDAQ:ONC) Issues Earnings Results, Beats Estimates By $0.65 EPS

BeOne Medicines (NASDAQ:ONC) issued its quarterly earnings data on Wednesday. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65, Zacks reports. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.

Here are the key takeaways from BeOne Medicines’ conference call:

• Q2 results exceeded expectations: Revenue reached $1.7 billion, up 30% year over year, while GAAP diluted EPS increased 144% to $2.05. The company raised 2026 revenue guidance by $300 million and GAAP operating-income guidance by $250 million.
• BRUKINSA continued its strong commercial momentum, generating more than $1.2 billion in global revenue, up 31%, with the highest sustained new-patient starts since launch and growth across all five approved indications. Management cited improving adherence, favorable early treatment duration and supportive real-world survival data.
• Pipeline and regulatory progress accelerated. FDA approval of BEQALZI in relapsed/refractory mantle cell lymphoma and positive Phase III MANGROVE results support a potential chemo-free frontline MCL regimen, with global submissions planned for the second half of 2026; several solid-tumor assets are also moving toward pivotal trials.
• The CELESTIMO 301 zanubrutinib/sonrotoclax regimen did not achieve statistical superiority on the uMRD endpoint versus venetoclax/obinutuzumab. The study will continue to its primary progression-free-survival endpoint, but the result introduces uncertainty despite management’s confidence in eventual PFS superiority.
• BeOne plans substantial continued investment in its pipeline, with 2027 operating expenses expected to grow at a rate similar to recent years. The company also announced a $300 million expansion of its Hopewell, New Jersey manufacturing site, while noting potential future biosimilar competition for XGEVA in its Amgen portfolio.

BeOne Medicines Price Performance

Shares of BeOne Medicines stock traded up $6.18 during trading on Wednesday, hitting $329.19. The stock had a trading volume of 281,163 shares, compared to its average volume of 279,300. The business has a fifty day moving average of $293.98 and a two-hundred day moving average of $308.75. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The firm has a market cap of $36.12 billion, a P/E ratio of 73.65 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ONC. Guggenheim increased their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Citizens Jmp reaffirmed a “market outperform” rating and set a $396.00 price target on shares of BeOne Medicines in a report on Wednesday, July 1st. Nomura raised BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Finally, Royal Bank Of Canada increased their price target on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $394.00.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, insider Lai Wang sold 1,068 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $276.74, for a total value of $295,558.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 61,397 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99. Following the transaction, the chief executive officer owned 9,180 shares of the company’s stock, valued at approximately $2,916,210.60. This trade represents a 86.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 344,404 shares of company stock valued at $105,264,141 in the last ninety days. 6.19% of the stock is owned by insiders.

Institutional Investors Weigh In On BeOne Medicines

Several large investors have recently modified their holdings of the stock. Cetera Investment Advisers purchased a new stake in shares of BeOne Medicines during the second quarter valued at $455,000. Rhumbline Advisers acquired a new stake in BeOne Medicines during the 2nd quarter worth about $275,000. Arrowstreet Capital Limited Partnership purchased a new stake in BeOne Medicines during the second quarter valued at about $505,000. Invesco Ltd. acquired a new position in shares of BeOne Medicines in the second quarter worth about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of BeOne Medicines in the second quarter worth approximately $68,000. 48.55% of the stock is owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.